Ipilimumab retreatment in patients with pretreated advanced melanoma: The expanded access programme in Italy

British Journal of Cancer

Volumn 110, Issue 7, 2014, Pages 1721-1726

  Chiarion Sileni, V ^a   Pigozzo, J ^a   Ascierto, P A ^b   Simeone, E ^b   Maio, M ^c   Calabro L ^c   Marchetti, P ^d,e   De Galitiis, F ^d   Testori, A ^f   Ferrucci, P F ^f   Queirolo, P ^g   Spagnolo, F ^g   Quaglino, P ^h   Carnevale Schianca, F ⁱ   Mandala M ^j   Di Guardo, L ^k   Del Vecchio, M ^k  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

^d LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ CANDIOLO CANCER INSTITUTE   (Italy)

^j PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^k NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

disease control; expanded access; ipilimumab; melanoma; retreatment; safety; treatment outcome

Indexed keywords

IPILIMUMAB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW APLASIA; CANCER CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); COMPASSIONATE USE; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPOKALEMIA; HYPOTHYROIDISM; ITALY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; PATIENT PARTICIPATION; PRIORITY JOURNAL; PRURITUS; RETREATMENT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DISEASE PROGRESSION; FEMALE; HEALTH PLAN IMPLEMENTATION; HEALTH SERVICES ACCESSIBILITY; HUMANS; IMMUNOTHERAPY; ITALY; MALE; MELANOMA; MIDDLE AGED; PROGRAM DEVELOPMENT; REMISSION INDUCTION; RETREATMENT; SKIN NEOPLASMS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84897576238     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.126     Document Type: Article

References (33)

1. Agarwala SS (2009) Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 9: 587-595.
2. Chin K, Ibrahim R, Berman D, Yellin M, Lowy I, Lin R, Hoos A (2008) Treatment guidelines for the management of immune-related adverse events in patients treated with ipilimumab, an anti-CTLA4 therapy. Ann Oncol 19: viii244, abstract 787P.
3. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781.
4. Fong L, Small EJ (2008) Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 26: 5275-5283.
5. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gomez H, Bastholt L, Chasalow SD, Berman D (2011) A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 9: 204.
6. Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS (2011) A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs 29: 489-498.
7. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723.
8. Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R (2010) Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 37: 533-546.
9. Klebanoff CA, Gattinoni L, Restifo NP (2006) CD8\+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 211: 214-224.
10. Korman AJ, Peggs KS, Allison JP (2006) Checkpoint blockade in cancer immunotherapy. Adv Immunol 90: 297-339.
11. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, Parulekar W, Markovic SN, Saxman S, Kirkwood JM (2008) Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progressionfree and overall survival benchmarks for future phase II trials. J Clin Oncol 26: 527-534.
12. Lebbé C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, O'Day S, Chin KM, Opatt McDowell D, Cykowski L, McHenry B, Wolchok JD (2013) Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials. J Clin Oncol 31: abstract 9053.
13. Lens MB, Dawes M (2004) Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 150: 179-185.
14. Maio M, Bondarenko I, Robert C, Thomas L, Garbe C, Testori A, Lu H, Chin K, Wolchok J (2013) Survival analysis with 5 years of follow-up in a phase III study of ipilimumab and dacarbazine in metastatic melanoma. Eur J Cancer 49: abstract 3704.
15. Margolin KA, Hamid O, Weber JS, Pavlick AC, Hodi FS, Amin A, Bennett K, Michener T, Minor DR (2013) Ipilimumab retreatment following induction therapy: the expanded access program (EAP) experience. J Clin Oncol 31: abstract 9041.
16. Neyns B, Weber JS, Lebbé C, Maio M, Harmankaya K, Hamid O, O'Day S, Chin KM, Opatt McDowell D, Cykowski L, McHenry B, Wolchok JD (2013) Ipilimumab (Ipi) retreatment at 10 mg/kg in patients with metastatic melanoma previously treated in phase II trials. J Clin Oncol 31: abstract 9059.
17. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, Verschraegen C, Humphrey R, Ibrahim R, de Pril V, Hoos A, Wolchok JD (2010) Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 21: 1712-1717.
18. Peggs KS, Quezada SA, Korman AJ, Allison JP (2006) Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18: 206-213.
19. Pigozzo J, Ascierto PA, Calabrò L, De Galitiis F, Ferrucci PF, Queirolo P, Bernengo MG, Aglietta M, Mandalà M, Del Vecchio M (2012) Efficacy and safety of ipilimumab reinduction therapy in patients with pretreated advanced melanoma participating in an expanded access programme in Italy. Ann Oncol 23: abstract 1130P.
20. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ (2012) CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 18: 2039-2047.
21. Reiman JM, Kmieciak M, Manjili MH, Knutson KL (2007) Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol 17: 275-287.
22. Robert C, Ghiringhelli F (2009) What is the role of cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma? Oncologist 14: 848-861.
23. Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S (2013) Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res 19: 2232-2239.
24. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller Jr. WH, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526.
25. Schneider H, Downey J, Smith A, Zinselmeyer BH, Rush C, Brewer JM, Wei B, Hogg N, Garside P, Rudd CE (2006) Reversal of the TCR stop signal by CTLA-4. Science 313: 1972-1975.
26. Stewart TJ, Fernando GJ, Frazer IH, Leggatt GR (2004) Tumour susceptibility to innate and adaptive immunotherapy changes during tumour maturation. Immunol Cell Biol 82: 455-461.
27. Tarhini AA, Agostara B (2006) Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 19: 19-25.
28. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ (2009) A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15: 5591-5598.
29. Weber JS, Kahler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30: 2691-2697.
30. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15: 7412-7420.
31. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie Jr. T, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day SJ, Lebbe C (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11: 155-164.
32. Yamshchikov GV, Mullins DW, Chang CC, Ogino T, Thompson L, Presley J, Galavotti H, Aquila W, Deacon D, Ross W, Patterson JW, Engelhard VH, Ferrone S, Slingluff Jr CL (2005) Sequential immune escape and shifting of T-cell responses in a long-term survivor of melanoma. J Immunol 174: 6863-6871.
33. YERVOY Summary of Product Characteristics (2013) Available at http://www.medicines.org.uk/emc/medicine/247792013.